Erivedge
Erivedge Uses, Dosage, Side Effects, Food Interaction and all others data.
Erivedge inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012.
Erivedge selectively binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway.
| Trade Name | Erivedge |
| Availability | Prescription only |
| Generic | Vismodegib |
| Vismodegib Other Names | Vismodegib, Vismodégib, Vismodegibum |
| Related Drugs | fluorouracil topical, imiquimod topical, Efudex, Aldara, Libtayo, Erivedge |
| Weight | 150mg, |
| Type | Capsule, Oral Capsule |
| Formula | C19H14Cl2N2O3S |
| Weight | Average: 421.297 Monoisotopic: 420.010218428 |
| Protein binding | Vismodegib is highly protein bound with plasma protein binding at about 99%. Vismodegib binds to the plasma proteins, albumin and alpha-1-acid glycoprotein (saturable bnding). |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | Roche Products Limited |
| Available Country | Australia, Canada, United Kingdom, United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Erivedge is a hedgehog pathway inhibitor used to treat patients with locally advanced or metastatic basal cell carcinoma.
Erivedge is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
Erivedge is also used to associated treatment for these conditions: Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
How Erivedge works
Mutations of the Hedgehog pathway may results in uncontrolled proliferation of skin basal cells. Erivedge binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway.
Toxicity
Increased risk of embryo-fetal death and significant birth defects. Common adverse event include muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia.
Food Interaction
- Take with or without food. Food does not affect absorption.
Erivedge Drug Interaction
Moderate: diltiazemUnknown: charcoal, sulfamethoxazole / trimethoprim, ubiquinone, copper gluconate, glucose, ethanol, glycerin, heparin, arginine, levocarnitine, cysteine, lithium, valproic acid, thiamine, cyanocobalamin, pyridoxine, cholecalciferol, phytonadione, menaquinone
Erivedge Disease Interaction
Volume of Distribution
Erivedge has a volume of distribution of 16.4 to 26.6 L.
Elimination Route
The absolute bioavailability of a single dose is 31.8%. Absorption is saturable and is not affected by food.
Half Life
The half-life after a single dose is 12 days, and after continuous daily dosing is 4 days.
Elimination Route
Erivedge is mostly excreted unchanged, and the main route of elimination is by the feces (82%) and the urine accounts for 4.4%.
Innovators Monograph
You find simplified version here Erivedge
